Krabbe Disease
Also known as: Globoid Cell Leukodystrophy, Galactosylceramidase Deficiency
Krabbe disease is a rare, inherited lysosomal storage disorder that affects the nervous system. It results from a deficiency of the enzyme galactosylceramidase (GALC), leading to the accumulation of psychosine, a toxic galactolipid, in the brain and peripheral nerves. This accumulation damages the myelin sheath, the protective covering around nerve cells, causing neurological problems.
Krabbe disease is when your body can't break down certain fats, which hurts your brain and nerves. It makes it hard to move, see, and hear. Doctors can try to help with special treatments, but it's a very serious illness.
Signs & Symptoms
- Irritability
- Feeding difficulties
- Muscle stiffness and spasms
- Developmental delay
- Seizures
- Vision loss
- Hearing loss
- Progressive loss of motor skills
- Peripheral neuropathy
- Fever (unexplained)
- Vomiting
Treatment Options
Hematopoietic Stem Cell Transplantation (HSCT)
MODERATELY EFFECTIVEPhysical Therapy
SUPPORTIVEOccupational Therapy
SUPPORTIVENutritional Support
SUPPORTIVEMedications for symptom management (e.g., anti-seizure medications, muscle relaxants)
SUPPORTIVEDiagnosis
- Enzyme assay (GALC activity in leukocytes or fibroblasts)
- Genetic testing (GLAC gene sequencing)
- MRI of the brain (to assess myelin abnormalities)
- Nerve conduction studies (to assess peripheral nerve function)
- Newborn screening (in some regions)
History
Krabbe disease was first described by Danish neurologist Knud Krabbe in 1916. He identified the characteristic globoid cells in the brain tissue of affected individuals, leading to the initial designation of the disease as 'globoid cell leukodystrophy'. The enzymatic defect (GALC deficiency) was identified later, leading to a better understanding of the disease's pathophysiology.
Recent Breakthroughs
Gene Therapy Clinical Trials for Krabbe Disease
Several clinical trials are underway evaluating the safety and efficacy of gene therapy approaches for Krabbe disease. These trials aim to deliver a functional copy of the GALC gene to cells in the central nervous system, potentially preventing or slowing disease progression. Early results have shown promise, particularly in pre-symptomatic infants.
Improved Newborn Screening Methods
Advances in newborn screening technologies have led to more sensitive and specific methods for detecting Krabbe disease. This allows for earlier diagnosis and intervention, potentially improving outcomes with HSCT or other emerging therapies.